Post-traumatic stress disorder and obsessive-compulsive disorder are two of the most debilitating psychiatric conditions in clinical practice. Both are associated with significant functional impairment, high rates of treatment resistance, and a substantial gap between the number of people who need effective care and the number who receive it. Both have also historically been treated primarily through combinations of psychotherapy and medication that, while helpful for many patients, leave a significant proportion without adequate relief.
That picture is changing. TMS for PTSD and ketamine for OCD represent two of the most significant recent advances in the treatment of conditions that have long challenged conventional psychiatric approaches. Both are now available at qualified outpatient practices, both are backed by a growing body of clinical evidence, and both offer a different therapeutic mechanism from the medications that have previously dominated treatment for these conditions.
This article explains what each treatment involves, what the evidence shows, and what patients should understand before pursuing either option. Village TMS PTSD care and ketamine treatment are both offered at Village TMS in New York City, within a psychiatrically supervised outpatient setting.
TMS for PTSD: The Mechanism and the Evidence
PTSD involves dysregulation of the neural circuits that process threat, memory, and emotional response. The amygdala, which mediates fear responses, shows hyperactivity in PTSD, while the prefrontal cortex, which normally modulates and regulates amygdala activity, shows reduced function. This imbalance contributes to the hallmark symptoms of PTSD: intrusive memories, hypervigilance, emotional numbing, and avoidance.
TMS applied to the prefrontal cortex can modulate activity in these circuits, strengthening prefrontal regulation of the amygdala and reducing the hyperactivation that drives PTSD symptoms. Multiple TMS targets have been investigated for PTSD, including the right dorsolateral prefrontal cortex and medial prefrontal regions, with different targeting strategies showing meaningful reductions in symptom severity across studies.
The National Institute of Mental Health recognises PTSD as a serious condition requiring effective treatment, and the evidence base for TMS in PTSD has grown substantially in recent years. Several randomised controlled trials have demonstrated significant reductions in PTSD symptom severity following TMS treatment, including improvements in intrusion symptoms, hyperarousal, and avoidance, as well as secondary improvements in comorbid depression and anxiety.
TMS for PTSD is particularly relevant for patients who have not responded adequately to first-line treatments, which typically include trauma-focused cognitive behavioural therapy and SSRIs. It is also worth considering for patients who are unable to engage with trauma-focused psychotherapy due to the severity of their symptoms, where TMS may reduce symptom severity to a level that makes therapeutic engagement more feasible.
What TMS for PTSD Involves in Practice
TMS treatment for PTSD follows a broadly similar format to TMS for depression, involving daily outpatient sessions over a four to six week course. Sessions typically last between 20 and 40 minutes depending on the protocol, and patients remain awake and alert throughout, with no anaesthesia or sedation required.
The specific targeting and protocol used for PTSD may differ from the standard depression protocol. Providers experienced in TMS for PTSD will conduct an individualised evaluation and select the treatment parameters most likely to be effective based on your symptom profile and the current evidence. Ask specifically about the targeting approach and the evidence behind it when you consult with a provider.
TMS for PTSD is currently used in an off-label context, meaning it does not yet have a specific FDA clearance for PTSD in the same way it does for depression. This does not reflect a lack of evidence but rather the regulatory timeline for new indications. A reputable provider will be transparent about this and will discuss the evidence base and realistic expectations clearly.
Ketamine for OCD: The Mechanism and the Evidence
OCD is characterised by intrusive, unwanted thoughts and compulsive behaviours that are performed to neutralise the anxiety these thoughts produce. The primary treatment for OCD is exposure and response prevention therapy, a form of cognitive behavioural therapy that has the strongest evidence base of any psychological treatment for the condition. SSRIs, particularly at higher doses than are typically used for depression, are also effective for many patients.
However, OCD has a significant treatment-resistant population. Up to 40 percent of patients do not achieve adequate symptom control with first-line treatments, and for these patients the options have historically been limited. Ketamine for OCD represents one of the most promising emerging treatments for this group.
The rationale for ketamine for OCD lies in the glutamate hypothesis of OCD. There is substantial evidence that glutamatergic dysregulation in the cortico-striato-thalamo-cortical circuits that are implicated in OCD plays a role in the pathophysiology of the condition. Ketamine, as an NMDA receptor antagonist that modulates glutamate signalling, targets these circuits directly.
Several small but carefully conducted trials have demonstrated rapid reductions in OCD symptom severity following ketamine administration, with effects appearing within hours and persisting for days to weeks after a single infusion. The magnitude of the effect in some studies has been remarkable, with patients who have had severe, debilitating OCD for years reporting substantial symptom reduction within 24 hours of treatment.
Important Considerations for Ketamine in OCD
The evidence for ketamine in OCD, while promising, is less extensive than the evidence for ketamine in depression. Most studies to date have been small and have examined single infusions rather than full treatment courses. The optimal dosing schedule, the durability of effects, and the patient characteristics that predict response are all areas where more research is needed.
This means that patients considering ketamine for OCD should approach the treatment as a complement to, rather than a replacement for, established OCD treatments. The most thoughtful clinical approach combines ketamine with ongoing exposure and response prevention therapy, using the window of symptom reduction that ketamine provides to facilitate more effective engagement with psychological treatment.
A qualified provider will discuss these considerations with you honestly, including the current limitations of the evidence base, before recommending ketamine for OCD. Be cautious of providers who present ketamine as a straightforward cure for OCD without acknowledging the complexity of the evidence.
Finding Qualified Providers for Both Treatments
Both TMS for PTSD and ketamine for OCD require providers with specific expertise and clinical infrastructure. Key criteria apply to both:
- Psychiatric evaluation: both treatments should begin with a thorough psychiatric assessment that confirms the diagnosis, reviews treatment history, and determines whether the treatment is appropriate for your specific clinical picture
- Clinical experience: ask specifically about the provider’s experience with TMS for PTSD or ketamine for OCD, not just their general TMS or ketamine experience
- Coordination with psychotherapy: both treatments work best as part of a broader treatment plan that includes appropriate psychotherapy. A provider who can coordinate with your therapist or who has therapists embedded in the practice is better positioned to maximise your outcomes
- Honest communication about evidence: a reputable provider will be transparent about what the evidence shows, including its limitations, and will set realistic expectations rather than overpromising
- Follow-up planning: both treatments may require maintenance or repeat courses depending on your response. Understanding the long-term treatment plan before you begin helps you make an informed decision
Final Thoughts
TMS for PTSD and ketamine for OCD represent genuine progress in the treatment of two conditions that have historically been among the most difficult to treat effectively. They are not simple fixes, and they are not appropriate for every patient. But for the right patient, with the right clinical support and the right expectations, both treatments offer a level of relief that conventional approaches have frequently been unable to provide.
The field is moving quickly. Patients who explore these options now, with qualified providers and realistic expectations, are at the leading edge of what psychiatric treatment can currently offer.
